Alpha- Antitrypsin Deficiency - Market Insight, Epidemiology and Market Forecast - 2027
SKU ID :DEL-11470848 | Published Date: 01-Jan-2018 | No. of pages: 100Description
TOC
1. Report Introduction
2. Alpha- Antitrypsin Deficiency Market Overview at a Glance
2.1. Market Share Distribution of Alpha- Antitrypsin Deficiency in 2017
2.2. Market Share Distribution of Alpha- Antitrypsin Deficiency in 2027
3. Disease Background and Overview: Alpha- Antitrypsin Deficiency
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Alpha- Antitrypsin Deficiency in 7MM
4.3. Total Prevalent Patient Population of Alpha- Antitrypsin Deficiency in 7MM – By Countries
5. Epidemiology of Alpha- Antitrypsin Deficiency by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Alpha- Antitrypsin Deficiency
5.1.3. Sub-Type Specific cases of the Alpha- Antitrypsin Deficiency *
5.1.4. Sex- Specific Cases of the Alpha- Antitrypsin Deficiency *
5.1.5. Diagnosed Cases of the Alpha- Antitrypsin Deficiency
5.1.6. Treatable Cases of the Alpha- Antitrypsin Deficiency
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Alpha- Antitrypsin Deficiency
5.4.3. Sub-Type Specific cases of the Alpha- Antitrypsin Deficiency *
5.4.4. Sex- Specific Cases of the Alpha- Antitrypsin Deficiency *
5.4.5. Diagnosed Cases of the Alpha- Antitrypsin Deficiency
5.4.6. Treatable Cases of the Alpha- Antitrypsin Deficiency
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Alpha- Antitrypsin Deficiency
5.5.3. Sub-Type Specific cases of the Alpha- Antitrypsin Deficiency *
5.5.4. Sex- Specific Cases of the Alpha- Antitrypsin Deficiency *
5.5.5. Diagnosed Cases of the Alpha- Antitrypsin Deficiency
5.5.6. Treatable Cases of the Alpha- Antitrypsin Deficiency
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Alpha- Antitrypsin Deficiency
5.6.3. Sub-Type Specific cases of the Alpha- Antitrypsin Deficiency *
5.6.4. Sex- Specific Cases of the Alpha- Antitrypsin Deficiency *
5.6.5. Diagnosed Cases of the Alpha- Antitrypsin Deficiency
5.6.6. Treatable Cases of the Alpha- Antitrypsin Deficiency
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Alpha- Antitrypsin Deficiency
5.7.3. Sub-Type Specific cases of the Alpha- Antitrypsin Deficiency *
5.7.4. Sex- Specific Cases of the Alpha- Antitrypsin Deficiency *
5.7.5. Diagnosed Cases of the Alpha- Antitrypsin Deficiency
5.7.6. Treatable Cases of the Alpha- Antitrypsin Deficiency
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Alpha- Antitrypsin Deficiency
5.8.3. Sub-Type Specific cases of the Alpha- Antitrypsin Deficiency *
5.8.4. Sex- Specific Cases of the Alpha- Antitrypsin Deficiency *
5.8.5. Diagnosed Cases of the Alpha- Antitrypsin Deficiency
5.8.6. Treatable Cases of the Alpha- Antitrypsin Deficiency
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Alpha- Antitrypsin Deficiency
5.9.3. Sub-Type Specific cases of the Alpha- Antitrypsin Deficiency *
5.9.4. Sex- Specific Cases of the Alpha- Antitrypsin Deficiency *
5.9.5. Diagnosed Cases of the Alpha- Antitrypsin Deficiency
5.9.6. Treatable Cases of the Alpha- Antitrypsin Deficiency
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Alpha- Antitrypsin Deficiency
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Alpha- Antitrypsin Deficiency
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Alpha- Antitrypsin Deficiency : 7MM Market Analysis
12.1. 7MM Market Size of Alpha- Antitrypsin Deficiency
12.2. 7MM Percentage Share of drugs marketed for Alpha- Antitrypsin Deficiency
12.3. 7MM Market Sales of Alpha- Antitrypsin Deficiency by Products
13. Alpha- Antitrypsin Deficiency : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Alpha- Antitrypsin Deficiency in United States
13.1.2. Percentage Share of drugs marketed for Alpha- Antitrypsin Deficiency in United States
13.1.3. Market Sales of Alpha- Antitrypsin Deficiency by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Alpha- Antitrypsin Deficiency in Germany
13.2.1.2. Percentage Share of drugs marketed for Alpha- Antitrypsin Deficiency in Germany
13.2.1.3. Market Sales of Alpha- Antitrypsin Deficiency by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Alpha- Antitrypsin Deficiency in France
13.2.2.2. Percentage Share of drugs marketed for Alpha- Antitrypsin Deficiency in France
13.2.2.3. Market Sales of Alpha- Antitrypsin Deficiency by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Alpha- Antitrypsin Deficiency in Italy
13.2.3.2. Percentage Share of drugs marketed for Alpha- Antitrypsin Deficiency in Italy
13.2.3.3. Market Sales of Alpha- Antitrypsin Deficiency by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Alpha- Antitrypsin Deficiency in Spain
13.2.4.2. Percentage Share of drugs marketed for Alpha- Antitrypsin Deficiency in Spain
13.2.4.3. Market Sales of Alpha- Antitrypsin Deficiency by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Alpha- Antitrypsin Deficiency in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Alpha- Antitrypsin Deficiency in United Kingdom
13.2.5.3. Market Sales of Alpha- Antitrypsin Deficiency by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Alpha- Antitrypsin Deficiency in Japan
13.3.2. Percentage Share of drugs marketed for Alpha- Antitrypsin Deficiency in Japan
13.3.3. Market Sales of Alpha- Antitrypsin Deficiency by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
*Indication Specific
Tables & Figures
Table 1: Total Prevalent/Incident Cases of the Alpha- Antitrypsin Deficiency in 7MM
Table 2: Total Prevalent/Incident Cases of the Alpha- Antitrypsin Deficiency in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Alpha- Antitrypsin Deficiency in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Alpha- Antitrypsin Deficiency in United States (2016-2027)
Table 5: Sex- Specific Cases of the Alpha- Antitrypsin Deficiency in United States (2016-2027)
Table 6: Diagnosed Cases of the Alpha- Antitrypsin Deficiency in United States (2016-2027)
Table 7: Treatable Cases of the Alpha- Antitrypsin Deficiency in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Alpha- Antitrypsin Deficiency in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Alpha- Antitrypsin Deficiency in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Alpha- Antitrypsin Deficiency in Germany (2016-2027)
Table 11: Diagnosed Cases of the Alpha- Antitrypsin Deficiency in Germany (2016-2027)
Table 12: Treatable Cases of the Alpha- Antitrypsin Deficiency in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Alpha- Antitrypsin Deficiency in France (2016-2027)
Table 14: Sub-Type Specific cases of the Alpha- Antitrypsin Deficiency in France (2016-2027)
Table 15: Sex- Specific Cases of the Alpha- Antitrypsin Deficiency in France (2016-2027)
Table 16: Diagnosed Cases of the Alpha- Antitrypsin Deficiency in France (2016-2027)
Table 17: Treatable Cases of the Alpha- Antitrypsin Deficiency in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Alpha- Antitrypsin Deficiency in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Alpha- Antitrypsin Deficiency in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Alpha- Antitrypsin Deficiency in Italy (2016-2027)
Table 21: Diagnosed Cases of the Alpha- Antitrypsin Deficiency in Italy (2016-2027)
Table 22: Treatable Cases of the Alpha- Antitrypsin Deficiency in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Alpha- Antitrypsin Deficiency in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Alpha- Antitrypsin Deficiency in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Alpha- Antitrypsin Deficiency in Spain (2016-2027)
Table 26: Diagnosed Cases of the Alpha- Antitrypsin Deficiency in Spain (2016-2027)
Table 27: Treatable Cases of the Alpha- Antitrypsin Deficiency in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Alpha- Antitrypsin Deficiency in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Alpha- Antitrypsin Deficiency in UK (2016-2027)
Table 30: Sex- Specific Cases of the Alpha- Antitrypsin Deficiency in UK (2016-2027)
Table 31: Diagnosed Cases of the Alpha- Antitrypsin Deficiency in UK (2016-2027)
Table 32: Treatable Cases of the Alpha- Antitrypsin Deficiency in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Alpha- Antitrypsin Deficiency in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Alpha- Antitrypsin Deficiency in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Alpha- Antitrypsin Deficiency in Japan (2016-2027)
Table 36: Diagnosed Cases of the Alpha- Antitrypsin Deficiency in Japan (2016-2027)
Table 37: Treatable Cases of the Alpha- Antitrypsin Deficiency in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Alpha- Antitrypsin Deficiency in USD MM (2016-2027)
Table 42:7MM- Market Share Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Alpha- Antitrypsin Deficiency in USD MM (2016-2027)
Table 45: United States-Market Share Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Alpha- Antitrypsin Deficiency in USD MM (2016-2027)
Table 48: Germany-Market Share Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Alpha- Antitrypsin Deficiency in USD MM (2016-2027)
Table 51: France-Market Share Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Alpha- Antitrypsin Deficiency in USD MM (2016-2027)
Table 54: Italy-Market Share Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Alpha- Antitrypsin Deficiency in USD MM (2016-2027)
Table 57: Spain-Market Share Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Alpha- Antitrypsin Deficiency in USD MM (2016-2027)
Table 60:UK-Market Share Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Alpha- Antitrypsin Deficiency in USD MM (2016-2027)
Table 63: Japan-Market Share Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Figure 1: Total Prevalent/Incident Cases of the Alpha- Antitrypsin Deficiency in 7MM
Figure 2: Total Prevalent/Incident Cases of the Alpha- Antitrypsin Deficiency in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Alpha- Antitrypsin Deficiency in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Alpha- Antitrypsin Deficiency in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Alpha- Antitrypsin Deficiency in United States (2016-2027)
Figure 6: Diagnosed Cases of the Alpha- Antitrypsin Deficiency in United States (2016-2027)
Figure 7: Treatable Cases of the Alpha- Antitrypsin Deficiency in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Alpha- Antitrypsin Deficiency in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Alpha- Antitrypsin Deficiency in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Alpha- Antitrypsin Deficiency in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Alpha- Antitrypsin Deficiency in Germany (2016-2027)
Figure 12: Treatable Cases of the Alpha- Antitrypsin Deficiency in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Alpha- Antitrypsin Deficiency in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Alpha- Antitrypsin Deficiency in France (2016-2027)
Figure 15: Sex- Specific Cases of the Alpha- Antitrypsin Deficiency in France (2016-2027)
Figure 16: Diagnosed Cases of the Alpha- Antitrypsin Deficiency in France (2016-2027)
Figure 17: Treatable Cases of the Alpha- Antitrypsin Deficiency in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Alpha- Antitrypsin Deficiency in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Alpha- Antitrypsin Deficiency in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Alpha- Antitrypsin Deficiency in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Alpha- Antitrypsin Deficiency in Italy (2016-2027)
Figure 22: Treatable Cases of the Alpha- Antitrypsin Deficiency in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Alpha- Antitrypsin Deficiency in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Alpha- Antitrypsin Deficiency in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Alpha- Antitrypsin Deficiency in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Alpha- Antitrypsin Deficiency in Spain (2016-2027)
Figure 27: Treatable Cases of the Alpha- Antitrypsin Deficiency in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Alpha- Antitrypsin Deficiency in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Alpha- Antitrypsin Deficiency in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Alpha- Antitrypsin Deficiency in UK (2016-2027)
Figure 31: Diagnosed Cases of the Alpha- Antitrypsin Deficiency in UK (2016-2027)
Figure 32: Treatable Cases of the Alpha- Antitrypsin Deficiency in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Alpha- Antitrypsin Deficiency in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Alpha- Antitrypsin Deficiency in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Alpha- Antitrypsin Deficiency in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Alpha- Antitrypsin Deficiency in Japan (2016-2027)
Figure 37: Treatable Cases of the Alpha- Antitrypsin Deficiency in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Alpha- Antitrypsin Deficiency in USD MM (2016-2027)
Figure 42:7MM- Market Share Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Alpha- Antitrypsin Deficiency in USD MM (2016-2027)
Figure 45: United States-Market Share Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Alpha- Antitrypsin Deficiency in USD MM (2016-2027)
Figure 48: Germany-Market Share Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Alpha- Antitrypsin Deficiency in USD MM (2016-2027)
Figure 51: France-Market Share Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Alpha- Antitrypsin Deficiency in USD MM (2016-2027)
Figure 54: Italy-Market Share Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Alpha- Antitrypsin Deficiency in USD MM (2016-2027)
Figure 57: Spain-Market Share Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Alpha- Antitrypsin Deficiency in USD MM (2016-2027)
Figure 60:UK-Market Share Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Alpha- Antitrypsin Deficiency in USD MM (2016-2027)
Figure 63: Japan-Market Share Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Alpha- Antitrypsin Deficiency by Therapies in USD MM (2016-2027)
Companies
- PRICE
-
$6250$18750